Journal of the National Comprehensive Cancer Network

Papers
(The H4-Index of Journal of the National Comprehensive Cancer Network is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parent958
HSR22-175: Impact of ‘Choosing Wisely’ on Unnecessary Staging Imaging in Patients With Early Stage Breast Cancer: A Seer-Medicare Analysis838
HSR22-122: Racial Disparities in Breast Cancer-Specific Survival Among Women Aged 40 Years or Younger in the United States776
QIM22-193: Development and Implementation of a Scheduling Tool to Improve Patient Access to Outpatient Care in an Academic Cancer Center668
CLO22-063: Study on Correlation Between Serum CA 19-9 and Colorectal Carcinoma With Normal CEA651
NCCN News565
CLO21-029: Impact of Comorbidity Patterns on the Outcomes of Older Patients With Diffuse Large B- Cell Lymphoma516
Abstracts From the NCCN 2022 Annual Conference423
HSR21-064: The Effectiveness of Psychological Intervention on Reducing Distress in Patients With Prostate Cancer: A Literature Meta-Analysis352
HSR22-123: Breaking Cost Barriers in Treatment With Biosimilars–Improvement in Affordability of Trastuzumab Against HER2 Positive Breast Cancer Amongst Indian Women350
HSR22-138: Oncologist’s Perceptions on Immune Checkpoint Inhibitor Therapies for Non-Small Cell Lung Cancer315
CLO22-045: Gastrointestinal Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma (BCC): A Systematic Review and Meta-analysis305
HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting269
NCCN News215
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance213
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology212
NCCN News205
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility205
QIM21-082: Germline Testing in Pancreatic Adenocarcinoma: A Single Academic Center Experience201
NCCN News199
CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials188
CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients172
YIA22-008: Identification of Biomarkers That Predict Responses to Immunotherapy in Merkel Cell Carcinoma171
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021157
Application of the Socioecological Model to Regional Clinical Trials: A Paradigm-Shift to Advance Scientific Discovery and Prognostic Modeling155
CGE22-101: Dynamically Accumulating Homologous Recombination Deficiency (HRD) Status Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer150
Letter to the Editor Re: Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial141
Highlights of the NCCN Oncology Research Program118
HSR21-075: CancerSupportSource®-Caregiver: Psychometric Properties of 2-Item Depression and Anxiety Risk Screening Measures for Informal Cancer Caregivers106
Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers104
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)100
BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients73
Management of Recurrent or Metastatic Cervical Cancer72
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal72
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?69
BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer66
CLO22-073: Familial Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Associated to Novel PTCH1 Mutation c.1067 + 2T>C of Paternal Origin in Somatic Mosaicism With Marked Phenotypic Variation in the Chi61
HSR22-174: Are We ‘Choosing Wisely’? A Case of Unnecessary Staging Imaging in Older Patients With Prostate Cancer61
QIM22-191: Expansion of Tobacco Cessation Treatment Within the Stanford Cancer Institute: 6-Month and 24-Month Outcomes60
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!60
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC57
My Report Card56
Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing53
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Pha52
Highlights of the NCCN Oncology Research Program51
PCL22-187: Functional Role of TREM2 in NASH and HCC Development49
Highlights of the NCCN Oncology Research Program49
QIM23-132: Do EHR-Embedded Clinical Decision Support Tools Reduce Variation in Care? A Pre and Post-Implementation Comparison of Regimen Ordering Variation at a Multi-Site Community Cancer Clinic47
0.13567399978638